Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03570697 · ClinicalTrials.gov registry record · Phase 3
Imaging of Coronary Plaques in Participants Treated With Evolocumab
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 164
- Enrollment target
NCT03570697 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 164 participants.
The verdict
NCT03570697, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 164 participants
- Enrollment target
Study Summary
To evaluate the effect of evolocumab on fibrous cap thickness (FCT) in participants with non-ST-elevation acute coronary syndrome (NSTE-ACS) who are taking maximally tolerated statin therapy.
Interventions
- DRUG Placebo
- DRUG Evolocumab
- DRUG Statin therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2018-11-19 |
| Est. Completion | 2021-01-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03570697
The ClinicalTrials.gov registry entry for NCT03570697 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03570697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03570697 about?
NCT03570697 is a clinical study titled "Imaging of Coronary Plaques in Participants Treated With Evolocumab". To evaluate the effect of evolocumab on fibrous cap thickness (FCT) in participants with non-ST-elevation acute coronary syndrome (NSTE-ACS) who are taking maximally tolerated statin therapy.
What is the current status of trial NCT03570697?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 164 participants. The study started on 2018-11-19. Estimated completion is 2021-01-21.
What interventions are being tested in trial NCT03570697?
The interventions under investigation include: Placebo (DRUG), Evolocumab (DRUG), Statin therapy (DRUG).
Who is sponsoring clinical trial NCT03570697?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.